Table 3. Virologic responses in HIV-infected patients with chronic HCV genotype 1/6 or genotype 2/3 infection.
| Virologic response* | Genotype 1/6 (n = 53) |
Genotype 2/3 (n = 39) |
p value† | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arm A (n = 12) | Arm B (n = 10) | Arm C (n = 16) | Arm D (n = 11) | Arm E (n = 4) | All (A-E) (n = 53) | Arm F (n = 28) | Arm G (n = 11) | Arm H (n = 0) | All (F-H) (n = 39) | ||
| RVR | 12 (100) | 10 (100) | 0 (0) | 0 (0) | 0 (0) | 22 (41) | 28 (100) | 0 (0) | — | 28 (72) | 0.006 |
| Wk-8R | — | — | 16 (100) | 0 (0) | 0 (0) | — | — | — | — | — | — |
| EVR | 12 (100) | 10 (100) | 16 (100) | 11 (100) | 0 (0) | 49 (92) | 28 (100) | 11 (100) | — | 39 (100) | 0.13 |
| ETVR | 12 (100) | 10 (100) | 15 (94) | 10 (91) | 0 (0) | 47 (89) | 28 (100) | 11 (100) | — | 39 (100) | 0.04 |
| SVR | 11 (92) | 9 (90) | 12 (75) | 4 (36) | 0 (0) | 36 (68) | 23 (82) | 7 (64) | — | 30 (77) | 0.48 |
| Non—SVR | 1 (8) | 1 (10) | 4 (25) | 7 (64) | 4 (100) | 17 (32) | 3 (11) | 6 (55) | — | 9 (23) | |
| Relapse | 1 (8) | 1 (10) | 2 (13) | 5 (45) | 0 (0) | 9 (17) | 2 (7) | 4 (36) | — | 6 (15) | |
| No response | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (100) | 4 (8) | 0 (0) | 0 (0) | — | 0 (0) | |
| Breakthrough | 0 (0) | 0 (0) | 1 (6) | 1 (9) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | — | 0 (0) | |
| Undetermined | 0 (0) | 0 (0) | 1 (6) | 1 (9) | 0 (0) | 2 (4) | 1 (4) | 2 (18) | — | 3 (8) | |
HIV, human immunodeficiency virus; HCV, hepatitis C virus; RVR, rapid virologic response; Wk-8R, week 8 virologic response; EVR, early virologic response; ETVR, end-of-treatment virologic response; SVR, sustained virologic response.
*Values are numbers (percentages).
†Comparison for patients with HCV genotype 1/6 and HCV genotype 2/3 infections.